Compare Sanofi SA (SNY) vs Teucrium Soybean Fund (SOYB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sanofi SA vs Teucrium Soybean Fund — how do they compare? Sanofi SA trades at $43.7 (market cap $104.83B), while Teucrium Soybean Fund trades at $25.86. The key difference: Sanofi SA pays a 5.5% dividend while Teucrium Soybean Fund pays none, and Teucrium Soybean Fund is trading nearer its 52-week high, Sanofi SA nearer its low. Which is the better fit depends on your goals.
| SNY | SOYB | |
|---|---|---|
Market Cap | $104.83B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $52.34 | $25.88 |
52-Week Low | $41.33 | $21.07 |
Enterprise Value | $121.32B | — |
Dividend Yield | 5.5% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SNY trades at $43.97, down 1.55% today, with a bullish technical signal supported by moving averages. The company reported strong Q1 2026 earnings of $1.10 per share, beating expectations, and maintains robust profitability with a 71.92% gross margin. Recent FDA approval for Sarclisa's subcutaneous formulation and expanded AI research collaboration with Aqemia highlight ongoing innovation. Cash flow from operations remains healthy at $10.75 billion for 2025, though net cash flow is minimal at $49 million.
SNY presents a balanced investment case with solid fundamentals and analyst support (44% buy ratings), but faces risks from EU antitrust probes and patent expiration concerns for key drug Dupixent. Valuation metrics appear reasonable with P/E of 19.81 and P/B of 1.29. The stock's outlook depends on successful drug pipeline execution and navigating regulatory challenges, with current price levels offering stability near support.
SOYB is trading at $25.88, up 1.53% today with strong technical momentum as moving averages signal bullish sentiment. The stock shows mixed oscillator readings with RSI suggesting potential overbought conditions. Recent agricultural sector news highlights potential tailwinds from China's $17 billion crop purchase commitment through 2028, which could benefit agricultural companies.
The stock presents bullish technical positioning but requires fundamental validation through upcoming earnings reports. Key risks include commodity price volatility and execution challenges. Upside potential exists if the company can capitalize on agricultural export opportunities, though investors should await financial metric updates for proper valuation assessment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →About Teucrium Soybean Fund
SOYB is a commodity ETF that provides exposure to the price of soybean futures. It utilizes a laddered strategy by investing in several benchmark futures contracts to reduce the impact of roll costs and contango in the agricultural market.
Read more on SOYB →
